Dermatological adverse events associated with use of oral mechanistic target of rapamycin inhibitors in a cohort of individuals with tuberous sclerosis complex. (1st September 2020) - Pithadia, D.J.; Treichel, A.M.; Jones, A.M.; Julien‐Williams, P.; Machado, T.; Moss, J.; Darling, T.N.